Safety and efficacy outcomes of 3rd generation DES in an all‐comer population of patients undergoing PCI: 12‐month and 24‐month results of the e‐Biomatrix French registry

OBJECTIVES: The French Ebiomatrix registry aimed to confirm the results of the Leaders trial in an all‐comer population in France. BACKGROUND: The Leaders trial showed the Biolimus‐eluting‐sent (BES) to be equivalent to the Cypher stent in terms of safety and efficacy at 1 year and superior regardin...

Descripción completa

Detalles Bibliográficos
Autores principales: Maupas, Eric, Lipiecki, Janusz, Levy, Raphy, Faurie, Benjamin, Karsenty, Bernard, Moulichon, Marc Eric, Brunelle, François, Maillard, Luc, de Poli, Fabien, Lefèvre, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Coronary Artery Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724651/
https://www.ncbi.nlm.nih.gov/pubmed/28544186
http://dx.doi.org/10.1002/ccd.27081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724651/
https://www.ncbi.nlm.nih.gov/pubmed/28544186
http://dx.doi.org/10.1002/ccd.27081

Ejemplares similares